Patients exposed to both a BTKi and BCL-2i are a difficult-to-treat population with limited treatment options1,2

Current treatment options are associated with poor outcomes for patients who have been exposed to both a BTKi and BCL-2i after the immediate next line of therapy3*

Figures are based on real-world data of 548 patients with CLL or SLL exposed to both a BTKi and BCL-2i4*

Extremely rare CR3

 

34% ORR4*

 

13-month mDOR4*
(95% CI: 10.6, 19.5)

 

Achieving uMRD is uncommon5

Breyanzi® can offer your patients with 3L+ CLL or SLL a chance at complete response with a one-time infusion6†

*Data are from a retrospective observational study of 548 patients with CLL and exposure to both a BTKi and BCL-2i. The data utilized were from the Flatiron Health electronic health record-derived database, and originated from ~280 cancer clinics in the US. Patients had at least 2 clinic visits in the database showing evidence of receiving systemic therapy on or after January 1, 2011. Comparisons between real-world and clinical-trial data of patients with CLL should be made with caution.4

Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring.6

3L, third-line; BCL-2i, B-cell lymphoma 2 inhibitor; BTKi, Bruton tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; mDOR, median duration of response; ORR, overall response rate; SLL, small lymphocytic lymphoma; uMRD, undetectable minimal residual disease.

References

  1. Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):69. doi:10.1186/s13045-021-01054-w
  2. O’Brien SM, Furman RR, Byrd JC. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol. 2014;12(1 suppl 3):1-13.
  3. Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589-3596. doi:10.1158/1078-0432.CRR-19-3815
  4. Eyre TA, Hess LM, Sugihara T, et al. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023;64(5):1005-1016. doi:10.1080/10428194.2023.2190436
  5. Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357-2366. doi:10.1182/blood-2017-12-820910
  6. Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025.


Bristol Myers Squibb logo

© 2025 Juno Therapeutics, Inc., a Bristol Myers Squibb company. All Rights Reserved.
BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.
Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

© 2025 Bristol Myers Squibb company.

2009-US-2500225

09/2025